Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
-0.45 (-1.07%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 41.36 - 42.97
52 week 28.26 - 45.45
Open 41.85
Vol / Avg. 750,444.00/590,972.00
Mkt cap 1.74B
P/E 74.67
Div/yield     -
EPS 0.56
Shares 41.95M
Beta 1.32
Inst. own 108%
Feb 11, 2015
Q4 2014 Acorda Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Feb 10, 2015
Acorda Therapeutics Inc at Biotechnology Industry Organization CEO & Investor Conference - 2:30PM EST - Add to calendar
Jan 12, 2015
Acorda Therapeutics Inc at JPMorgan Healthcare Conference
Dec 2, 2014
Acorda Therapeutics Inc at Piper Jaffray Healthcare Conference
Nov 18, 2014
Acorda Therapeutics Inc at Stifel Healthcare Conference
Nov 11, 2014
Acorda Therapeutics Inc at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 11.28% 4.89%
Operating margin 19.66% 9.03%
EBITD margin - 11.11%
Return on average assets 5.00% 2.80%
Return on average equity 9.37% 3.98%
Employees 421 -
CDP Score - -


420 Saw Mill River Road
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Acorda Therapeutics, Inc. (Acorda) is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The Company�s Ampyra (dalfampridine) is used as a treatment to improve walking in patients with MS. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride. The Company is developing six clinical-stage therapies and one pre-clinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain and heart failure. It is also developing Plumiaz (trade name for Diazepam Nasal Spray), a nasal spray formulation of diazepam, for the treatment of people with epilepsy who experience cluster seizures, also known as acute repetitive seizures.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Michael W. Rogers Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Lauren M. Sabella Executive Vice President - Commercial Development
Age: 53
Bio & Compensation  - Reuters
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 57
Bio & Compensation  - Reuters
Enrique J. Carrazana M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Andrew Asa Hindman Chief Business Development Officer
Bio & Compensation  - Reuters
David W. Lawrence Chief - Business Operations
Age: 56
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 50
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters